Richa Chibbar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richa Chibbar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dana Mihalicz
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publicationJean Deschenes
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publicationJordan Nostedt
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publicationLevinus A. Dieleman
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication- Levinus A. Dieleman
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication Ross McLean
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication
Latest Publications
- Open Access
- 3 December 2020
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7
Refractory Celiac Disease Type II: A Case Report and Literature Review
We present an unusual case of 68-year-old male, who presented with acute abdomen, ulcerative jejunitis with perforation, and 2 months later with perforation of the sigmoid colon. We will also discuss difficulties in the delay in diagnosis of refractory celiac disease (RCD), specifically the atypical presentation, multiple surgeries, the consecutive failure of distinct therapeutic options, and multiple complications that occurred within the 3 months since first presentation.
- 3 December 2020
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7
Open AccessRefractory Celiac Disease Type II: A Case Report and Literature Review
We present an unusual case of 68-year-old male, who presented with acute abdomen, ulcerative jejunitis with perforation, and 2 months later with perforation of the sigmoid colon. We will also discuss difficulties in the delay in diagnosis of refractory celiac disease (RCD), specifically the atypical presentation, multiple surgeries, the consecutive failure of distinct therapeutic options, and multiple complications that occurred within the 3 months since first presentation.
- Open Access
The Gut Microbiota in Celiac Disease and probiotics
Celiac disease (CeD) is an immune-mediated enteropathy, and unique in that the specific trigger is known: gluten. The current mainstay of therapy is a gluten-free diet (GFD). As novel therapies are being developed, complementary strategies are also being studied, such as modulation of the gut microbiome. The gut microbiota is involved in the initiation and perpetuation of intestinal inflammation in several chronic diseases. Intestinal dysbiosis has been reported in CeD patients, untreated or treated with GFD, compared to healthy subjects. Several studies have identified differential bacterial populations associated with CeD patients and healthy subjects. However, it is still not clear if intestinal dysbiosis is the cause or effect of CeD. Probiotics have also been considered as a strategy to modulate the gut microbiome to an anti-inflammatory state. However, there is a paucity of data to support their use in treating CeD. Further studies are needed with therapeutic microbial formulations combined with human trials on the use of probiotics to treat CeD by restoring the gut microbiome to an anti-inflammatory state.
Open AccessThe Gut Microbiota in Celiac Disease and probiotics
Celiac disease (CeD) is an immune-mediated enteropathy, and unique in that the specific trigger is known: gluten. The current mainstay of therapy is a gluten-free diet (GFD). As novel therapies are being developed, complementary strategies are also being studied, such as modulation of the gut microbiome. The gut microbiota is involved in the initiation and perpetuation of intestinal inflammation in several chronic diseases. Intestinal dysbiosis has been reported in CeD patients, untreated or treated with GFD, compared to healthy subjects. Several studies have identified differential bacterial populations associated with CeD patients and healthy subjects. However, it is still not clear if intestinal dysbiosis is the cause or effect of CeD. Probiotics have also been considered as a strategy to modulate the gut microbiome to an anti-inflammatory state. However, there is a paucity of data to support their use in treating CeD. Further studies are needed with therapeutic microbial formulations combined with human trials on the use of probiotics to treat CeD by restoring the gut microbiome to an anti-inflammatory state.